- Albania / Albania
- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- Finland / Suomi
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
CHARLOTTE, N.C., US: Dentsply Sirona has announced that it has appointed Simon Campion as president and CEO. He will join the company’s board of directors from 12 September. Campion will succeed John Groetelaars, who was named interim CEO as part of a leadership reshuffle that included the dismissal of Donald Casey in April.
Eric K. Brandt, chairman of the Dentsply Sirona board of directors, said: “Simon’s appointment follows a comprehensive search process to identify the right leader to help the company deliver on its strategic and financial goals. Simon is a high-integrity, transformational leader with a record of world-class operational expertise and sustainable growth. In his 25 years in the medical device industry, Simon has led global business units, driven commercial execution, and developed and executed strategies to expand innovation and generate revenue growth at scale.”
Campion will join Dentsply Sirona from medical device company Becton, Dickinson and Company (BD), where he was appointed executive vice president and president of the medical segment in July. Prior to that he was the president of BD’s interventional segment, a position previously held by Groetelaars after the company’s acquisition of C. R. Bard in 2017. Campion previously held several leadership roles at C. R. Bard, including leading the surgery business unit.
Subsequent to Campion’s appointment, Dentsply Sirona’s board of directors has requested a full review of the company’s business and operations, including its competitive position and portfolio, margin improvement opportunities and capital structure. Since May, the company has been working with independent counsel and advisers to investigate potentially questionable financial practices. Only recently, the company announced that it had notified the NASDAQ markets that it cannot file its quarterly financial report in a timely manner. This was the second time Dentsply Sirona was unable to comply with the NASDAQ listing rules.
“During his tenure at BD, Simon delivered above-market annualised revenue growth, accelerated the segments’ [mergers and acquisitions] activity, and expanded the organic innovation agenda. We believe Simon’s values and leadership will be highly impactful in moving the company forward, particularly as the company prepares to complete the ongoing audit committee review, improve operational rigour, and drive accountability,” Brandt added.
Campion said, “It’s an honour to join Dentsply Sirona and have the opportunity to lead this great team. During my career, I’ve developed a clear understanding of what it takes for a global healthcare company to succeed, and I am confident that with its strong foundation of industry-leading products and patient-driven innovation, Dentsply Sirona is well positioned to capitalise on the market opportunities ahead and deliver long-term growth and value creation.”
Groetelaars, who will continue to serve on the board of directors, said: “It has been a privilege to serve as Dentsply Sirona’s interim CEO. Over the last several months, I’ve gained deep insight into Dentsply Sirona’s business, operations, and opportunities.”
Tue. 18 April 2023
11:00 am EST (New York)
Wed. 3 May 2023
8:00 am EST (New York)